Review
. 2007 Nov;66 Suppl 3(Suppl 3):iii77-80.
doi: 10.1136/ard.2007.078998.
Update on toll-like receptor-directed therapies for human disease
Affiliations
- PMID: 17934102
- PMCID: PMC2095280
- DOI: 10.1136/ard.2007.078998
Item in Clipboard
Review
Update on toll-like receptor-directed therapies for human disease
Ann Rheum Dis.
2007 Nov.
Abstract
Innate responses to microbes are mediated in large part by toll-like receptors (TLRs), which recognise a diverse range of molecules produced by viruses, bacteria and fungi. Great effort has been directed towards translating this knowledge into the development of new therapies for a wide spectrum of diseases, including infectious, malignant, autoimmune and allergic diseases. This review will provide a brief update on completed, ongoing and planned clinical trials of TLR ligand-based therapies for the treatment of diseases in humans.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
The future of toll-like receptor therapeutics.Curr Opin Mol Ther. 2008 Feb;10(1):21-31. Curr Opin Mol Ther. 2008. PMID: 18228178 Review.
-
Update on toll-like receptor ligands and allergy: implications for immunotherapy.Curr Allergy Asthma Rep. 2006 Sep;6(5):395-401. doi: 10.1007/s11882-996-0012-9. Curr Allergy Asthma Rep. 2006. PMID: 16899201 Review.
-
Immunology. Targeting the tolls.Science. 2006 Apr 14;312(5771):184-7. doi: 10.1126/science.312.5771.184. Science. 2006. PMID: 16614188 No abstract available.
-
[Responses with participation of toll-like receptors in protective immunity and in pathologic states].Ukr Biokhim Zh (1999). 2008 May-Jun;80(3):5-20. Ukr Biokhim Zh (1999). 2008. PMID: 18959023 Review. Ukrainian.
-
The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents.Immunopharmacol Immunotoxicol. 2009;31(3):331-8. doi: 10.1080/08923970902802926. Immunopharmacol Immunotoxicol. 2009. PMID: 19555209 Review.
Cited by
-
The Expression of Toll-like Receptors in Dermatological Diseases and the Therapeutic Effect of Current and Newer Topical Toll-like Receptor Modulators.J Clin Aesthet Dermatol. 2010 Sep;3(9):20-9. J Clin Aesthet Dermatol. 2010. PMID: 20877521 Free PMC article.
-
Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy.Front Immunol. 2023 Oct 23;14:1227833. doi: 10.3389/fimmu.2023.1227833. eCollection 2023. Front Immunol. 2023. PMID: 37936697 Free PMC article. Review.
-
E3 ligase RNF99 negatively regulates TLR-mediated inflammatory immune response via K48-linked ubiquitination of TAB2.Cell Death Differ. 2023 Apr;30(4):966-978. doi: 10.1038/s41418-023-01115-2. Epub 2023 Jan 21. Cell Death Differ. 2023. PMID: 36681779 Free PMC article.
-
Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA.Nature. 2008 Jul 24;454(7203):523-7. doi: 10.1038/nature07106. Epub 2008 Jun 11. Nature. 2008. PMID: 18548002 Free PMC article.
-
Metal-Based Nanoparticles and the Immune System: Activation, Inflammation, and Potential Applications.Biomed Res Int. 2015;2015:143720. doi: 10.1155/2015/143720. Epub 2015 Jun 1. Biomed Res Int. 2015. PMID: 26125021 Free PMC article. Review.
References
-
- Medzhitov R, Janeway C A., Jr Decoding the patterns of self and nonself by the innate immune system. Science 2002296298–300. - PubMed
-
- Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006124783–801. - PubMed
-
- Hoebe K, Janssen E, Beutler B. The interface between innate and adaptive immunity. Nat Immunol 20045971–974. - PubMed
-
- Rifkin I R, Leadbetter E A, Busconi L, Viglianti G, Marshak‐Rothstein A. Toll‐like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 200520427–42. - PubMed
-
- Ishii K J, Akira S. Innate immune recognition of nucleic acids: beyond toll‐like receptors. Int J Cancer 2005117517–523. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
